American Journalist Told How He Got Used To "Sputnik V"

American Journalist Told How He Got Used To "Sputnik V"
American Journalist Told How He Got Used To "Sputnik V"

Video: American Journalist Told How He Got Used To "Sputnik V"

Отличия серверных жестких дисков от десктопных
Video: Russia's Sputnik V vaccine: What the experts say | COVID-19 Special 2023, February

MOSCOW, 11 Feb - RIA Novosti. The correspondent of the American radio corporation National Public Radio Lucian Kim spoke about how he was vaccinated with the Sputnik V vaccine in Moscow.

The journalist received only the first vaccination and will return in three weeks for the second component. According to him, everything was very simple: he signed up for the nearest state polyclinic. He was able to get vaccinated against coronavirus thanks to the profession.

There was no queue at all, and Kim called the whole process well-organized and standard: the nurse gave the injection so that he did not even feel it.

Then the doctors gave him recommendations on how to behave in the coming days: do not go to the pool, sauna and gym. Alcohol should also be temporarily abandoned.

According to Kim, he feels great after the procedure. At the same time, he admitted that he had certain fears before vaccination.

"But I talked to experts, and none of those with whom I discussed this issue told me about any possible problems with the vaccine itself," the correspondent explained.

He recalled the publication of vaccine research results in the medical journal Lancet. The worries, as Kim explained, were more related to the transportation and storage of the drug, but Sputnik V, unlike other vaccines, can be stored in an ordinary medical refrigerator.

“In the end, I decided that Sputnik V was better than no protection at all,” Kim concluded.

Earlier, several foreign journalists reported about the vaccination with the Russian drug "Sputnik V": correspondents of the NRK television company Jan Espen Kruse and The New York Times Andrew Kramer.

Sputnik V was registered in August last year. It was developed by the Gamaleya National Research Center for Epidemiology and Microbiology with the support of RDIF based on the well-studied human adenovirus vector platform. As follows from the publication in the Lancet, the vaccine has shown high immunogenicity and safety. Its effectiveness was 91.6 percent, the drug provides complete protection against severe cases of COVID-19.

Read the full text on the Inosmi website >>

Popular by topic